Oruka Therapeutics (ORKA)

• Market cap: $1.31B
• 1 day: 2.65%
• 5 days: -3.87%
• 1 month: -1.46%
• 3 months: 80.53%
• 6 months: 178.89%
• Year to date: 35.6%
• 1 year: 12.83%
• 5 years: -44.28%
• 10 years: -97.52%
• Sector: Healthcare
• Industry: Biotechnology

About: Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Employees: 28